Aileron Therapeutics & Dana-Farber/Boston Children's Cancer and Blood Disorders Center Enters into a Clinical Collaboration to Treat Pediatric Patients with Cancer
Shots:
- The agreement involves onset of P-I trial including Pediatric Patients with solid tumors & acute leukemia receiving ALRN-6924 as a monotx & in combination with cytarabine
- With the above two studies- an additional study will be initiated involving biomarker with the approach to improve response rates
- ALRN-6924 is a novel dual inhibitor of MDM2/MDMX and is currently being evaluated to treat solid and hematological cancers- including AML- myelodysplastic syndrome (MDS)- and peripheral T-cell lymphoma (PTCL)
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
